# Targeted Oral Pill Daraxonrasib Receives FDA Approval After Doubling Survival Time for Advanced Pancreatic Cancer

> The US FDA has approved Daraxonrasib (brand name Rasonque), a pioneering once-daily oral targeted drug by Revolution Medicines that blocks mutated RAS proteins and nearly doubles median survival time for metastatic pancreatic cancer patients.

**Type:** article · **Category:** Health · **Published:** 2026-08-27 · **Source:** TrendKia
**Canonical:** https://trendkia.com/en/health/painakriyatika-kainsara-ke-khilapha-us-fda-ki-mnjuri-se-nai-ummida-daraxonrasib-rojana-eka-goli-se-marijon-ki-umra-doguni-karane-m-22886 · **Language:** English
**Tags:** Pancreatic Cancer, Daraxonrasib, US FDA Approval, Oncology Drug, Revolution Medicines, Targeted Therapy

In a major medical breakthrough for oncology, the US Food and Drug Administration (US FDA) has approved the world's first targeted molecular therapy that directly attacks the root genetic cause of pancreatic cancer. Developed by Revolution Medicines, the drug named Daraxonrasib will be commercialized in the United States under the brand name Rasonque. Formulated as a convenient oral pill, patients need to take the medication just once daily, marking a pivotal shift away from standard intravenous treatments for one of the world's most challenging malignancies.

## Clinical Trial Breakthrough: Median Survival Time Nearly Doubled

Pancreatic cancer has long been classified by medical experts as one of the most fatal and notoriously difficult-to-treat forms of cancer. Because the disease remains largely asymptomatic during its early progression, diagnosis typically occurs only in advanced or metastatic stages. For several decades, therapeutic research yielded very little progress, leaving the median survival rate for affected individuals practically stagnant despite advancements in generic chemotherapy regimens. However, clinical data submitted for Daraxonrasib demonstrates a dramatic step forward, nearly doubling the overall lifespan of patients compared to standard care.

According to clinical trial metrics, patients who received traditional standard-of-care chemotherapy exhibited a median survival duration of just 6.7 months. In stark contrast, participants who were administered the daily Daraxonrasib oral pill achieved a median survival duration of 13.2 months. Beyond extending life expectancy, the therapy successfully inhibits the aggressive proliferation of malignant cells and actively assists in shrinking existing tumor mass within the body.

## Mechanism of Action: Disrupting Mutated RAS Protein Signals

At the molecular level, the primary driver behind the vast majority of pancreatic cancers is a specific genetic mutation within the RAS protein family, particularly the KRAS mutation. Under normal cellular conditions, these proteins regulate cell growth; however, once mutated, they send continuous, uninhibited signals instructing cells to multiply rapidly and form invasive tumors. Traditional chemotherapy works broadly and often fails to halt this underlying molecular driver.

Daraxonrasib addresses this challenge directly by binding to and blocking the mutated RAS protein signaling pathway. By intercepting these abnormal biochemical transmissions, the drug starves cancer cells of vital growth instructions and metabolic energy. Deprived of these essential signals, the cancerous cells cease replication, causing the growth of the primary tumor to stall and preventing further systemic spread.

## Patient Eligibility and Approved Indications

The US FDA approval specifies clear clinical criteria for prescribing this targeted oral medication. The drug is authorized specifically for adult patients diagnosed with Metastatic Pancreatic Ductal Adenocarcinoma. In plain terms, this encompasses individuals whose pancreatic cancer has already metastasized or spread to other secondary organs and tissues throughout the body.

Furthermore, eligibility includes patients who have previously undergone at least one prior line of systemic therapy or conventional chemotherapy without experiencing clinical benefit or disease stabilization. It also provides a critical alternative for frail or vulnerable individuals who are unable to tolerate the severe, debilitating side effects associated with high-dose intravenous chemotherapy regimens.

## Global Implications and Relevance for Cancer Care in India

The severity of pancreatic cancer is underscored by global health statistics. Even in the United States, the 5-year survival rate for pancreatic cancer patients stands at approximately 13%. The approval of Daraxonrasib is particularly relevant for India, where the disease presents a heavy healthcare burden with roughly 10,000 new pancreatic cancer cases diagnosed annually. Furthermore, the 5-year survival rate in India remains critically low, hovering between just 7% and 10%.

Indian oncology experts anticipate that the global regulatory approval of targeted therapies like Daraxonrasib will fundamentally transform pancreatic cancer treatment protocols worldwide, including in India. In the coming years, as such molecular medications become globally accessible, advanced-stage patients in India may gain access to a daily oral treatment option that offers significantly better survival outcomes while sparing them the agony of repeated, heavy chemotherapy infusions.

## What this means for you
This approval marks a major milestone for pancreatic cancer patients, drastically improving survival prospects and treatment convenience.

- **In India:** India records nearly 10,000 new cases annually with a low 5-year survival rate of 7% to 10%. Future availability of this targeted therapy will provide Indian patients a daily oral pill option instead of grueling hospital-based chemotherapy infusions.

- **Globally:** Patients with advanced metastatic pancreatic cancer can potentially double their median survival time from 6.7 months to 13.2 months. This offers families precious additional time with improved quality of life.

- **Treatment Convenience:** Formulated as a once-daily oral pill, it eliminates the need for frequent hospital visits for invasive intravenous chemotherapy sessions.

- **Alternative for Sensitive Patients:** Because it specifically targets mutated signals rather than broadly killing cells, it provides a viable therapeutic option for patients unable to tolerate heavy chemotherapy side effects.

## Questions & Answers

### 1. What medical condition is Daraxonrasib approved to treat?
The US FDA has approved Daraxonrasib for adult patients suffering from Metastatic Pancreatic Ductal Adenocarcinoma.

### 2. What is the dosage form and frequency of Daraxonrasib?
Daraxonrasib is formulated as an oral pill that patients take once daily.

### 3. How much did Daraxonrasib extend survival in clinical trials?
Clinical trials showed that patients on Daraxonrasib achieved a median survival duration of 13.2 months compared to 6.7 months for those on standard chemotherapy.

### 4. How does Daraxonrasib work at the cellular level?
It directly blocks the mutated RAS protein signals that drive cancer cells to continuously replicate, halting tumor growth and cutting off energy supply.

### 5. What is the current pancreatic cancer burden in India?
India sees approximately 10,000 new cases of pancreatic cancer annually, with a 5-year survival rate hovering between 7% and 10%.

---
_TrendKia — Har trend, sabse pehle.. Machine-readable view; canonical HTML at the URL above._